Pavilion Health Today
Supporting healthcare professionals to deliver the best patient care

Patients with high-risk skin cancer have new treatment option

Hundreds of patients with a type of advanced skin cancer are set to benefit from a new treatment, dabrafenib plus trametinib.

Hundreds of patients with a type of advanced skin cancer are set to benefit from a new treatment, dabrafenib plus trametinib. NICE’s positive recommendation applies to adults who have stage III BRAF V600 mutation-positive melanoma that has spread to nearby lymph vessels or lymph glands, which make up an important part of the immune system. Dabrafenib plus trametinib would be given to patients who have already had surgery to remove the tumour and associated lymph glands. Called adjuvant therapy or treatment, it aims to remove any residual cancer left behind. Mirella Marlow, deputy director for the NICE Centre for Health Technology

---------------------------

This content is restricted to members of Pavilion Health Today. If you are an existing user, please log in. New users may register for free below.

Existing Users Log In
   
New User Registration
captcha
*Required field

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read more ...

Privacy & Cookies Policy